India · Delayed Price · Currency is INR Vilin Bio Med Statistics
Total Valuation
Vilin Bio Med has a market cap or net worth of INR 648.68 million. The enterprise value is 636.04 million.
| Market Cap | 648.68M |
| Enterprise Value | 636.04M |
Important Dates
The next estimated earnings date is Wednesday, August 12, 2026.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Vilin Bio Med has 13.95 million shares outstanding. The number of shares has increased by 0.92% in one year.
| Current Share Class | 13.95M |
| Shares Outstanding | 13.95M |
| Shares Change (YoY) | +0.92% |
| Shares Change (QoQ) | +4.18% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 33.94.
| PE Ratio | 33.94 |
| Forward PE | n/a |
| PS Ratio | 1.53 |
| PB Ratio | 2.29 |
| P/TBV Ratio | 2.29 |
| P/FCF Ratio | 161.68 |
| P/OCF Ratio | 92.93 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.92, with an EV/FCF ratio of 158.53.
| EV / Earnings | 32.98 |
| EV / Sales | 1.50 |
| EV / EBITDA | 19.92 |
| EV / EBIT | 21.87 |
| EV / FCF | 158.53 |
Financial Position
The company has a current ratio of 4.25, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.25 |
| Quick Ratio | 2.71 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.06 |
| Debt / FCF | 0.51 |
| Interest Coverage | 42.27 |
Financial Efficiency
Return on equity (ROE) is 7.50% and return on invested capital (ROIC) is 7.28%.
| Return on Equity (ROE) | 7.50% |
| Return on Assets (ROA) | 5.80% |
| Return on Invested Capital (ROIC) | 7.28% |
| Return on Capital Employed (ROCE) | 10.20% |
| Weighted Average Cost of Capital (WACC) | 7.81% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 1.35 |
| Inventory Turnover | 6.47 |
Taxes
In the past 12 months, Vilin Bio Med has paid 9.12 million in taxes.
| Income Tax | 9.12M |
| Effective Tax Rate | 32.11% |
Stock Price Statistics
The stock price has increased by +80.58% in the last 52 weeks. The beta is 0.64, so Vilin Bio Med's price volatility has been lower than the market average.
| Beta (5Y) | 0.64 |
| 52-Week Price Change | +80.58% |
| 50-Day Moving Average | 44.17 |
| 200-Day Moving Average | 31.87 |
| Relative Strength Index (RSI) | 53.60 |
| Average Volume (20 Days) | 16,000 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Vilin Bio Med had revenue of INR 422.63 million and earned 19.29 million in profits. Earnings per share was 1.37.
| Revenue | 422.63M |
| Gross Profit | 46.36M |
| Operating Income | 29.08M |
| Pretax Income | 28.41M |
| Net Income | 19.29M |
| EBITDA | 31.93M |
| EBIT | 29.08M |
| Earnings Per Share (EPS) | 1.37 |
Balance Sheet
The company has 14.70 million in cash and 2.06 million in debt, with a net cash position of 12.64 million or 0.91 per share.
| Cash & Cash Equivalents | 14.70M |
| Total Debt | 2.06M |
| Net Cash | 12.64M |
| Net Cash Per Share | 0.91 |
| Equity (Book Value) | 283.72M |
| Book Value Per Share | 19.75 |
| Working Capital | 209.41M |
Cash Flow
In the last 12 months, operating cash flow was 6.98 million and capital expenditures -2.97 million, giving a free cash flow of 4.01 million.
| Operating Cash Flow | 6.98M |
| Capital Expenditures | -2.97M |
| Depreciation & Amortization | 2.85M |
| Net Borrowing | -23.67M |
| Free Cash Flow | 4.01M |
| FCF Per Share | 0.29 |
Margins
Gross margin is 10.97%, with operating and profit margins of 6.88% and 4.56%.
| Gross Margin | 10.97% |
| Operating Margin | 6.88% |
| Pretax Margin | 6.72% |
| Profit Margin | 4.56% |
| EBITDA Margin | 7.56% |
| EBIT Margin | 6.88% |
| FCF Margin | 0.95% |
Dividends & Yields
Vilin Bio Med does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.92% |
| Shareholder Yield | -0.92% |
| Earnings Yield | 2.97% |
| FCF Yield | 0.62% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |